...transdermal granisetron patch has completed Phase I trials to treat chemotherapy-induced nausea and vomiting (CINV). ProStrakan said AB-1001...
...can deliver the same dosage of granisetron in a smaller patch than its marketed Sancuso transdermal granisetron patch...
...were not disclosed. SymBio Pharmaceuticals Ltd. (Tokyo, Japan) has rights to AB-1001, which it calls SyB D-0701...

...Healthcare S.A. (Pazzallo, Switzerland). ProStrakan's sales force will market Gelclair to oncologists alongside its Sancuso transdermal granisetron patch...

...for Sancuso to prevent chemotherapy-induced nausea and vomiting (CINV). The company plans to launch the transdermal granisetron patch...

...for Sancuso to prevent chemotherapy-induced nausea and vomiting (CINV). The company plans to launch the transdermal granisetron patch...

...for Sancuso to prevent chemotherapy-induced nausea and vomiting (CINV). The company plans to launch the transdermal granisetron patch...

...Corp., and ProStrakan Group plc to smooth the U.S. commercialization of the British company’s Sancuso transdermal granisetron patch...

...as AB-1001. Abeille Pharmaceuticals Inc. , Princeton, N.J. SymBio Pharmaceuticals Ltd. , Tokyo, Japan Product: SyB D-0701...
...Abeille Pharmaceuticals Inc. , Princeton, N.J. SymBio Pharmaceuticals Ltd. , Tokyo, Japan Product: SyB D-0701 ( AB-1001...

...pushed back to July 18 (see BioCentury, July 14). ProStrakan still plans to launch the transdermal granisetron patch...

...the agency. The company expects a decision this quarter and still plans to launch the transdermal granisetron patch...

...Friday. The original PDUFA date was May 2. The company still plans to launch the transdermal granisetron patch...